BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wu XZ, Xie GR, Chen D. Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma. J Gastroenterol Hepatol 2007;22:1178-82. [PMID: 17559361 DOI: 10.1111/j.1440-1746.2007.04997.x] [Cited by in Crossref: 132] [Cited by in F6Publishing: 124] [Article Influence: 8.8] [Reference Citation Analysis]
Number Citing Articles
1 Altomonte J, Braren R, Schulz S, Marozin S, Rummeny EJ, Schmid RM, Ebert O. Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats. Hepatology 2008;48:1864-73. [PMID: 19003878 DOI: 10.1002/hep.22546] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 1.9] [Reference Citation Analysis]
2 Lu W, Lan Y, Xiao K, Xu Q, Qu L, Chen Q, Huang T, Gao J, Zhao Y. BODIPY-Mn nanoassemblies for accurate MRI and phototherapy of hypoxic cancer. J Mater Chem B 2017;5:1275-83. [DOI: 10.1039/c6tb02575g] [Cited by in Crossref: 18] [Cited by in F6Publishing: 1] [Article Influence: 3.6] [Reference Citation Analysis]
3 Moser C, Lang SA, Mori A, Hellerbrand C, Schlitt HJ, Geissler EK, Fogler WE, Stoeltzing O. ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo. BMC Cancer 2008;8:206. [PMID: 18651980 DOI: 10.1186/1471-2407-8-206] [Cited by in Crossref: 48] [Cited by in F6Publishing: 38] [Article Influence: 3.4] [Reference Citation Analysis]
4 Carbajo-Pescador S, Ordoñez R, Benet M, Jover R, García-Palomo A, Mauriz JL, González-Gallego J. Inhibition of VEGF expression through blockade of Hif1α and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells. Br J Cancer. 2013;109:83-91. [PMID: 23756865 DOI: 10.1038/bjc.2013.285] [Cited by in Crossref: 140] [Cited by in F6Publishing: 136] [Article Influence: 15.6] [Reference Citation Analysis]
5 Heng-jun G, Yao-jun Z, Min-shan C, Mei-xian C, Jun-ting H, Li X, Lau WY. Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma. Liver Int 2014;34:612-20. [DOI: 10.1111/liv.12307] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
6 Tu T, Budzinska MA, Maczurek AE, Cheng R, Di Bartolomeo A, Warner FJ, McCaughan GW, McLennan SV, Shackel NA. Novel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and development. Int J Mol Sci. 2014;15:9422-9458. [PMID: 24871369 DOI: 10.3390/ijms15069422] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 5.9] [Reference Citation Analysis]
7 Zhang B, Tang B, Gao J, Li J, Kong L, Qin L. A hypoxia-related signature for clinically predicting diagnosis, prognosis and immune microenvironment of hepatocellular carcinoma patients. J Transl Med 2020;18:342. [PMID: 32887635 DOI: 10.1186/s12967-020-02492-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
8 Li Y, Wang W, Xu X, Sun S, Qu XJ. {2-[1-(3-Methoxycarbonylmethyl-1H-indol-2-yl)-1-methyl-ethyl]-1H-indol-3-yl}-acetic acid methyl ester (MIAM) inhibited human hepatocellular carcinoma growth through upregulation of Sirtuin-3 (SIRT3). Biomed Pharmacother 2015;69:125-32. [PMID: 25661348 DOI: 10.1016/j.biopha.2014.11.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
9 Jeng KS, Chang CF, Jeng WJ, Sheen IS, Jeng CJ. Heterogeneity of hepatocellular carcinoma contributes to cancer progression. Crit Rev Oncol Hematol. 2015;94:337-347. [PMID: 25680939 DOI: 10.1016/j.critrevonc.2015.01.009] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 6.9] [Reference Citation Analysis]
10 Cervello M, Bachvarov D, Lampiasi N, Cusimano A, Azzolina A, McCubrey JA, Montalto G. Molecular mechanisms of sorafenib action in liver cancer cells. Cell Cycle. 2012;11:2843-2855. [PMID: 22801548 DOI: 10.4161/cc.21193] [Cited by in Crossref: 85] [Cited by in F6Publishing: 90] [Article Influence: 8.5] [Reference Citation Analysis]
11 Lawless MW, O’Byrne KJ, Gray SG. Targeting oxidative stress in cancer. Expert Opin Ther Targets. 2010;14:1225-1245. [PMID: 20942747 DOI: 10.1517/14728222.2010.526933] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 4.1] [Reference Citation Analysis]
12 Dev A, Sood A, Choudhury SR, Karmakar S. Paclitaxel nanocrystalline assemblies as a potential transcatheter arterial chemoembolization (TACE) candidate for unresectable hepatocellular carcinoma. Materials Science and Engineering: C 2020;107:110315. [DOI: 10.1016/j.msec.2019.110315] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
13 Yoo JJ, Lee DH, Cho Y, Cho EJ, Lee JH, Yu SJ, Kim YJ, Kim CY, Yoon JH. Differential sensitivity of hepatocellular carcinoma cells to suppression of hepatocystin transcription under hypoxic conditions. J Bioenerg Biomembr 2016;48:581-90. [PMID: 27640193 DOI: 10.1007/s10863-016-9677-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
14 Tohme S, Yazdani HO, Liu Y, Loughran P, van der Windt DJ, Huang H, Simmons RL, Shiva S, Tai S, Tsung A. Hypoxia mediates mitochondrial biogenesis in hepatocellular carcinoma to promote tumor growth through HMGB1 and TLR9 interaction. Hepatology 2017;66:182-97. [PMID: 28370295 DOI: 10.1002/hep.29184] [Cited by in Crossref: 47] [Cited by in F6Publishing: 53] [Article Influence: 9.4] [Reference Citation Analysis]
15 Chen J, Jin R, Zhao J, Liu J, Ying H, Yan H, Zhou S, Liang Y, Huang D, Liang X, Yu H, Lin H, Cai X. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma. Cancer Letters 2015;367:1-11. [DOI: 10.1016/j.canlet.2015.06.019] [Cited by in Crossref: 111] [Cited by in F6Publishing: 121] [Article Influence: 15.9] [Reference Citation Analysis]
16 Liu WB, Xu GL, Jia WD, Li JS, Ma JL, Chen K, Wang ZH, Ge YS, Ren WH, Yu JH. Prognostic significance and mechanisms of patterned matrix vasculogenic mimicry in hepatocellular carcinoma. Med Oncol. 2011;28 Suppl 1:S228-S238. [PMID: 20957524 DOI: 10.1007/s12032-010-9706-x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 47] [Article Influence: 3.5] [Reference Citation Analysis]
17 Zubiete-Franco I, García-Rodríguez JL, Lopitz-Otsoa F, Serrano-Macia M, Simon J, Fernández-Tussy P, Barbier-Torres L, Fernández-Ramos D, Gutiérrez-de-Juan V, López de Davalillo S, Carlevaris O, Beguiristain Gómez A, Villa E, Calvisi D, Martín C, Berra E, Aspichueta P, Beraza N, Varela-Rey M, Ávila M, Rodríguez MS, Mato JM, Díaz-Moreno I, Díaz-Quintana A, Delgado TC, Martínez-Chantar ML. SUMOylation regulates LKB1 localization and its oncogenic activity in liver cancer. EBioMedicine 2019;40:406-21. [PMID: 30594553 DOI: 10.1016/j.ebiom.2018.12.031] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
18 Flamant L, Roegiers E, Pierre M, Hayez A, Sterpin C, De Backer O, Arnould T, Poumay Y, Michiels C. TMEM45A is essential for hypoxia-induced chemoresistance in breast and liver cancer cells. BMC Cancer 2012;12:391. [PMID: 22954140 DOI: 10.1186/1471-2407-12-391] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 4.8] [Reference Citation Analysis]
19 Wu MS, Lien GS, Shen SC, Yang LY, Chen YC. HSP90 Inhibitors, Geldanamycin and Radicicol, Enhance Fisetin-Induced Cytotoxicity via Induction of Apoptosis in Human Colonic Cancer Cells. Evid Based Complement Alternat Med 2013;2013:987612. [PMID: 23840275 DOI: 10.1155/2013/987612] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
20 Fan Z, Yang G, Zhang W, Liu Q, Liu G, Liu P, Xu L, Wang J, Yan Z, Han H, Liu R, Shu M. Hypoxia blocks ferroptosis of hepatocellular carcinoma via suppression of METTL14 triggered YTHDF2-dependent silencing of SLC7A11. J Cell Mol Med 2021;25:10197-212. [PMID: 34609072 DOI: 10.1111/jcmm.16957] [Reference Citation Analysis]
21 You N, Liu W, Tang L, Zhong X, Ji R, Zhang N, Wang D, He Y, Dou K, Tao K. Tg737 signaling is required for hypoxia-enhanced invasion and migration of hepatoma cells. J Exp Clin Cancer Res. 2012;31:75. [PMID: 22974282 DOI: 10.1186/1756-9966-31-75] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
22 Pleguezuelo M, Marelli L, Misseri M, Germani G, Calvaruso V, Xiruochakis E, Pinelopi M, Burroughs AK. TACE versus TAE as therapy for hepatocellular carcinoma. Expert Rev Anticancer Ther. 2008;8:1623-1641. [PMID: 18925854 DOI: 10.1586/14737140.8.10.1623] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 4.3] [Reference Citation Analysis]
23 Borde T, Laage Gaupp F, Geschwind JF, Savic LJ, Miszczuk M, Rexha I, Adam L, Walsh JJ, Huber S, Duncan JS, Peters DC, Sinusas A, Schlachter T, Gebauer B, Hyder F, Coman D, van Breugel JMM, Chapiro J. Idarubicin-Loaded ONCOZENE Drug-Eluting Bead Chemoembolization in a Rabbit Liver Tumor Model: Investigating Safety, Therapeutic Efficacy, and Effects on Tumor Microenvironment. J Vasc Interv Radiol 2020;31:1706-1716.e1. [PMID: 32684417 DOI: 10.1016/j.jvir.2020.04.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 De Bock K, Mazzone M, Carmeliet P. Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? Nat Rev Clin Oncol. 2011;8:393-404. [PMID: 21629216 DOI: 10.1038/nrclinonc.2011.83] [Cited by in Crossref: 191] [Cited by in F6Publishing: 182] [Article Influence: 17.4] [Reference Citation Analysis]
25 Huang M, Wang L, Chen J, Bai M, Zhou C, Liu S, Lin Q. Regulation of COX-2 expression and epithelial-to-mesenchymal transition by hypoxia-inducible factor-1α is associated with poor prognosis in hepatocellular carcinoma patients post TACE surgery. Int J Oncol 2016;48:2144-54. [PMID: 26984380 DOI: 10.3892/ijo.2016.3421] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
26 Hsu MH, Wu SC, Pao KC, Unlu I, Gnabre JN, Mold DE, Huang RC, Hwu JR. Hepatocellular carcinoma targeting agents: conjugates of nitroimidazoles with trimethyl nordihydroguaiaretic acid. ChemMedChem 2014;9:1030-7. [PMID: 24648164 DOI: 10.1002/cmdc.201300521] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
27 Torgersen J, Kallan MJ, Carbonari DM, Park LS, Mehta RL, D'Addeo K, Tate JP, Lim JK, Goetz MB, Rodriguez-Barradas MC, Bräu N, Brown ST, Taddei TH, Justice AC, Lo Re V 3rd. Brief Report: Accuracy of FIB-4 for Cirrhosis in People Living With HIV and Hepatocellular Carcinoma. J Acquir Immune Defic Syndr 2020;85:530-4. [PMID: 33185999 DOI: 10.1097/QAI.0000000000002510] [Reference Citation Analysis]
28 Wang K, Duan C, Zou X, Song Y, Li W, Xiao L, Peng J, Yao L, Long Q, Liu L. Increased mediator complex subunit 15 expression is associated with poor prognosis in hepatocellular carcinoma. Oncol Lett 2018;15:4303-13. [PMID: 29556287 DOI: 10.3892/ol.2018.7820] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
29 Lin J, Wu L, Bai X, Xie Y, Wang A, Zhang H, Yang X, Wan X, Lu X, Sang X, Zhao H. Combination treatment including targeted therapy for advanced hepatocellular carcinoma. Oncotarget 2016;7:71036-51. [PMID: 27626176 DOI: 10.18632/oncotarget.11954] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
30 Huang F, Chen J, Lan R, Wang Z, Chen R, Lin J, Zhang L, Fu L. δ-Catenin peptide vaccines repress hepatocellular carcinoma growth via CD8+ T cell activation. Oncoimmunology 2018;7:e1450713. [PMID: 30221043 DOI: 10.1080/2162402X.2018.1450713] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
31 Yılmaz Y, Güneş A, Topel H, Atabey N. Signaling Pathways as Potential Therapeutic Targets in Hepatocarcinogenesis. J Gastrointest Cancer 2017;48:225-37. [PMID: 28819741 DOI: 10.1007/s12029-017-9958-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
32 Byun J, Kim SY, Kim JH, Kim MJ, Yoo C, Shim JH, Lee SS. Prediction of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma using imaging features of gadoxetic acid-enhanced magnetic resonance imaging. Acta Radiol 2020;:284185120971844. [PMID: 33197329 DOI: 10.1177/0284185120971844] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Peng WX, Xiong EM, Ge L, Wan YY, Zhang CL, Du FY, Xu M, Bhat RA, Jin J, Gong AH. Egr-1 promotes hypoxia-induced autophagy to enhance chemo-resistance of hepatocellular carcinoma cells. Exp Cell Res 2016;340:62-70. [PMID: 26708617 DOI: 10.1016/j.yexcr.2015.12.006] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
34 Vandewynckel YP, Laukens D, Geerts A, Vanhove C, Descamps B, Colle I, Devisscher L, Bogaerts E, Paridaens A, Verhelst X. Therapeutic effects of artesunate in hepatocellular carcinoma: repurposing an ancient antimalarial agent. Eur J Gastroenterol Hepatol. 2014;26:861-870. [PMID: 24987823 DOI: 10.1097/MEG.0000000000000066] [Cited by in Crossref: 24] [Cited by in F6Publishing: 11] [Article Influence: 3.4] [Reference Citation Analysis]
35 Stechele M, Wittgenstein H, Stolzenburg N, Schnorr J, Neumann J, Schmidt C, Günther RW, Streitparth F. Novel MR-Visible, Biodegradable Microspheres for Transcatheter Arterial Embolization: Experimental Study in a Rabbit Renal Model. Cardiovasc Intervent Radiol 2020;43:1515-27. [PMID: 32514611 DOI: 10.1007/s00270-020-02534-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Tang Y, Liu S, Li N, Guo W, Shi J, Yu H, Zhang L, Wang K, Liu S, Cheng S. 14-3-3ζ promotes hepatocellular carcinoma venous metastasis by modulating hypoxia-inducible factor-1α. Oncotarget 2016;7:15854-67. [PMID: 26910835 DOI: 10.18632/oncotarget.7493] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
37 Hu B, Yang XB, Sang XT. Development and Verification of the Hypoxia-Related and Immune-Associated Prognosis Signature for Hepatocellular Carcinoma. J Hepatocell Carcinoma 2020;7:315-30. [PMID: 33204664 DOI: 10.2147/JHC.S272109] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
38 Gnutzmann D, Kortes N, Sumkauskaite M, Schmitz A, Weiss KH, Radeleff B. Transvascular therapy of Hepatocellular Carcinoma (HCC), status and developments. Minim Invasive Ther Allied Technol 2018;27:69-80. [PMID: 29381102 DOI: 10.1080/13645706.2018.1432489] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
39 Zhu AX, Duda DG, Sahani DV, Jain RK. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol 2011;8:292-301. [PMID: 21386818 DOI: 10.1038/nrclinonc.2011.30] [Cited by in Crossref: 293] [Cited by in F6Publishing: 302] [Article Influence: 26.6] [Reference Citation Analysis]
40 Ambade A, Satishchandran A, Szabo G. Alcoholic hepatitis accelerates early hepatobiliary cancer by increasing stemness and miR-122-mediated HIF-1α activation. Sci Rep 2016;6:21340. [PMID: 26888602 DOI: 10.1038/srep21340] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 7.7] [Reference Citation Analysis]
41 Min L, Ling W, Hua R, Qi H, Chen S, Wang H, Tang L, Shangguan W. Anti‑angiogenic therapy for normalization of tumor vasculature: A potential effect of Buyang Huanwu decoction on nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Mol Med Rep 2016;13:2518-26. [PMID: 26846752 DOI: 10.3892/mmr.2016.4854] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
42 Jindal A, Thadi A, Shailubhai K. Hepatocellular Carcinoma: Etiology and Current and Future Drugs. J Clin Exp Hepatol 2019;9:221-32. [PMID: 31024205 DOI: 10.1016/j.jceh.2019.01.004] [Cited by in Crossref: 62] [Cited by in F6Publishing: 66] [Article Influence: 20.7] [Reference Citation Analysis]
43 Jhaveri KS, Cleary SP, Fischer S, Haider MA, Pargoankar V, Khalidi K, Moshonov H, Gallinger S. Blood oxygen level-dependent liver MRI: can it predict microvascular invasion in HCC? J Magn Reson Imaging. 2013;37:692-699. [PMID: 23125092 DOI: 10.1002/jmri.23858] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
44 Lee NO, Park JW, Lee JA, Shim JH, Kong SY, Kim KT, Lee YS. Dual action of a selective cyclooxygenase-2 inhibitor on vascular endothelial growth factor expression in human hepatocellular carcinoma cells: novel involvement of discoidin domain receptor 2. J Cancer Res Clin Oncol 2012;138:73-84. [PMID: 22009181 DOI: 10.1007/s00432-011-1075-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
45 Li YM, Yao DF. Molecular composition, activation mechanism of hypoxia-inducible factor-1 and targeted therapy of hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2008; 16(27): 3070-3076 [DOI: 10.11569/wcjd.v16.i27.3070] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
46 Zhou C, Liu J, Tang Y, Zhu G, Zheng M, Jiang J, Yang J, Liang X. Coexpression of hypoxia-inducible factor-2α, TWIST2, and SIP1 may correlate with invasion and metastasis of salivary adenoid cystic carcinoma. J Oral Pathol Med. 2012;41:424-431. [PMID: 22103974 DOI: 10.1111/j.1600-0714.2011.01114.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
47 Takahashi K, Yan IK, Wood J, Haga H, Patel T. Involvement of extracellular vesicle long noncoding RNA (linc-VLDLR) in tumor cell responses to chemotherapy. Mol Cancer Res. 2014;12:1377-1387. [PMID: 24874432 DOI: 10.1158/1541-7786.MCR-13-0636] [Cited by in Crossref: 152] [Cited by in F6Publishing: 104] [Article Influence: 19.0] [Reference Citation Analysis]
48 Cha H, Yoon HI, Lee IJ, Koom WS, Han KH, Seong J. Clinical factors related to recurrence after hepatic arterial concurrent chemoradiotherapy for advanced but liver-confined hepatocellular carcinoma. J Radiat Res. 2013;54:1069-1077. [PMID: 23633620 DOI: 10.1093/jrr/rrt034] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
49 Radeleff B, Stampfl U, Sommer C, Bellemann N, Hoffmann K, Ganten T, Ehehalt R, Kauczor H. Transvaskuläre Ablation des hepatozellulären Karzinoms: Ist Chemotherapie alles? Radiologe 2012;52:44-55. [DOI: 10.1007/s00117-011-2211-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
50 Ambade A, Satishchandran A, Saha B, Gyongyosi B, Lowe P, Kodys K, Catalano D, Szabo G. Hepatocellular carcinoma is accelerated by NASH involving M2 macrophage polarization mediated by hif-1αinduced IL-10. Oncoimmunology 2016;5:e1221557. [PMID: 27853646 DOI: 10.1080/2162402X.2016.1221557] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
51 Wang XJ, Feng CW, Li M. ADAM17 mediates hypoxia-induced drug resistance in hepatocellular carcinoma cells through activation of EGFR/PI3K/Akt pathway. Mol Cell Biochem. 2013;380:57-66. [PMID: 23625205 DOI: 10.1007/s11010-013-1657-z] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 4.4] [Reference Citation Analysis]
52 Mauriz E, Carbajo-pescador S, Ordoñez R, García-fernández MC, Mauriz JL, Lechuga LM, González-gallego J. On-line surface plasmon resonance biosensing of vascular endothelial growth factor signaling in intact-human hepatoma cell lines. Analyst 2014;139:1426. [DOI: 10.1039/c3an02211k] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
53 Qi X, Wong BL, Lau SH, Ng KT, Kwok SY, Kin-Wai Sun C, Tzang FC, Shao Y, Li CX, Geng W, Ling CC, Ma YY, Liu XB, Liu H, Liu J, Yeung WH, Lo CM, Man K. A hemoglobin-based oxygen carrier sensitized Cisplatin based chemotherapy in hepatocellular carcinoma. Oncotarget 2017;8:85311-25. [PMID: 29156721 DOI: 10.18632/oncotarget.19672] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
54 Korse CM, Bonfrer JMG, Prevoo W, Baas P, Taal BG. Increase of angiogenic growth factors after hepatic artery embolization in patients with neuroendocrine tumours. Tumor Biol 2011;32:647-52. [DOI: 10.1007/s13277-011-0164-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
55 Gaba RC, Yap FY, Martinez EM, Li Y, Guzman G, Parvinian A, van Breemen RB, Kumar N. Transarterial sorafenib chemoembolization: preliminary study of technical feasibility in a rabbit model. J Vasc Interv Radiol 2013;24:744-50. [PMID: 23510657 DOI: 10.1016/j.jvir.2013.01.488] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
56 Shen G, Li X, Jia YF, Piazza GA, Xi Y. Hypoxia-regulated microRNAs in human cancer. Acta Pharmacol Sin 2013;34:336-41. [PMID: 23377548 DOI: 10.1038/aps.2012.195] [Cited by in Crossref: 93] [Cited by in F6Publishing: 92] [Article Influence: 10.3] [Reference Citation Analysis]
57 Anavi S, Madar Z, Tirosh O. Non-alcoholic fatty liver disease, to struggle with the strangle: Oxygen availability in fatty livers. Redox Biol. 2017;13:386-392. [PMID: 28667907 DOI: 10.1016/j.redox.2017.06.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
58 Virmani S, Rhee TK, Ryu RK, Sato KT, Lewandowski RJ, Mulcahy MF, Kulik LM, Szolc-Kowalska B, Woloschak GE, Yang GY, Salem R, Larson AC, Omary RA. Comparison of hypoxia-inducible factor-1alpha expression before and after transcatheter arterial embolization in rabbit VX2 liver tumors. J Vasc Interv Radiol 2008;19:1483-9. [PMID: 18922400 DOI: 10.1016/j.jvir.2008.06.017] [Cited by in Crossref: 60] [Cited by in F6Publishing: 63] [Article Influence: 4.6] [Reference Citation Analysis]
59 Nielsen DL, Sengeløv L. Inhibition of placenta growth factor with TB-403: a novel antiangiogenic cancer therapy. Expert Opin Biol Ther 2012;12:795-804. [PMID: 22506966 DOI: 10.1517/14712598.2012.679655] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
60 Shneor D, Folberg R, Pe'er J, Honigman A, Frenkel S. Stable knockdown of CREB, HIF-1 and HIF-2 by replication-competent retroviruses abrogates the responses to hypoxia in hepatocellular carcinoma. Cancer Gene Ther 2017;24:64-74. [PMID: 27934882 DOI: 10.1038/cgt.2016.68] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
61 Hernandez-Gea V, Toffanin S, Friedman SL, Llovet JM. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology. 2013;144:512-527. [PMID: 23313965 DOI: 10.1053/j.gastro.2013.01.002] [Cited by in Crossref: 395] [Cited by in F6Publishing: 387] [Article Influence: 43.9] [Reference Citation Analysis]
62 Shi Q, Li T, Huang S, Bai Y, Wang Y, Liu J, Zhou C, Chen Y, Xiong B. Transcatheter Arterial Embolization Containing Donafenib Induces Anti-Angiogenesis and Tumoricidal CD8+ T-Cell Infiltration in Rabbit VX2 Liver Tumor. Cancer Manag Res 2021;13:6943-52. [PMID: 34522137 DOI: 10.2147/CMAR.S328294] [Reference Citation Analysis]
63 Orlacchio A, Chegai F, Francioso S, Merolla S, Monti S, Angelico M, Tisone G, Mannelli L. Repeated Transarterial Chemoembolization with Degradable Starch 
Microspheres (DSMs-TACE) of Unresectable Hepatocellular Carcinoma: A Prospective Pilot Study. Curr Med Imaging Rev 2018;14:637-45. [PMID: 30197583 DOI: 10.2174/1573405613666170616123657] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
64 Corona-villalobos CP, Kamel IR. Functional Volumetric MRI in Assessing Treatment Response to Intra-Arterial Therapy of Primary and Secondary Liver Tumors: . Journal of Computer Assisted Tomography 2014;38:513-7. [DOI: 10.1097/rct.0000000000000072] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
65 Monnier J, Boissan M, L’Helgoualc’h A, Lacombe ML, Turlin B, Zucman-Rossi J, Théret N, Piquet-Pellorce C, Samson M. CXCR7 is up-regulated in human and murine hepatocellular carcinoma and is specifically expressed by endothelial cells. Eur J Cancer. 2012;48:138-148. [PMID: 21778049 DOI: 10.1016/j.ejca.2011.06.044] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 5.1] [Reference Citation Analysis]
66 Lang SA, Moser C, Fichnter-Feigl S, Schachtschneider P, Hellerbrand C, Schmitz V, Schlitt HJ, Geissler EK, Stoeltzing O. Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice. Hepatology. 2009;49:523-532. [PMID: 19085954 DOI: 10.1002/hep.22685] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 3.2] [Reference Citation Analysis]
67 Santhakumar C, Gane EJ, Liu K, Mccaughan GW. Current perspectives on the tumor microenvironment in hepatocellular carcinoma. Hepatol Int 2020;14:947-57. [DOI: 10.1007/s12072-020-10104-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
68 Szabo G. Alcoholic Liver Disease Accelerates Early Hepatocellular Cancer in a Mouse Model. Adv Exp Med Biol 2018;1032:71-9. [PMID: 30362091 DOI: 10.1007/978-3-319-98788-0_5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
69 Gaba RC, Groth JV, Parvinian A, Guzman G, Casadaban LC. Gene expression in hepatocellular carcinoma: pilot study of potential transarterial chemoembolization response biomarkers. J Vasc Interv Radiol 2015;26:723-32. [PMID: 25724086 DOI: 10.1016/j.jvir.2014.12.610] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
70 Yang SH, Lin J, Lu F, Dai YY, Han ZH, Fu CX, Hu FL, Gu HC. Contrast-enhanced susceptibility weighted imaging with ultrasmall superparamagnetic iron oxide improves the detection of tumor vascularity in a hepatocellular carcinoma nude mouse model. J Magn Reson Imaging 2016;44:288-95. [PMID: 26808392 DOI: 10.1002/jmri.25167] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
71 Abbattista MR, Jamieson SM, Gu Y, Nickel JE, Pullen SM, Patterson AV, Wilson WR, Guise CP. Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma. Cancer Biol Ther 2015;16:610-22. [PMID: 25869917 DOI: 10.1080/15384047.2015.1017171] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
72 Liao ZH, Zhu HQ, Chen YY, Chen RL, Fu LX, Li L, Zhou H, Zhou JL, Liang G. The epigallocatechin gallate derivative Y6 inhibits human hepatocellular carcinoma by inhibiting angiogenesis in MAPK/ERK1/2 and PI3K/AKT/ HIF-1α/VEGF dependent pathways. J Ethnopharmacol 2020;259:112852. [PMID: 32278759 DOI: 10.1016/j.jep.2020.112852] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
73 Zou X, Pan T, Jiang J, Li G, Song C, Sun R, Yang Z, Sun D, Hou C, Chen M, Tian Y. Poly(ε-caprolactone)-containing graft copolymers for ratiometric extracellular oxygen sensing. Sensors and Actuators B: Chemical 2017;248:108-18. [DOI: 10.1016/j.snb.2017.03.126] [Cited by in Crossref: 10] [Article Influence: 2.0] [Reference Citation Analysis]
74 Xue X, Gao W, Sun B, Xu Y, Han B, Wang F, Zhang Y, Sun J, Wei J, Lu Z, Zhu Y, Sato Y, Sekido Y, Miao Y, Kondo Y. Vasohibin 2 is transcriptionally activated and promotes angiogenesis in hepatocellular carcinoma. Oncogene 2013;32:1724-34. [PMID: 22614011 DOI: 10.1038/onc.2012.177] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 5.2] [Reference Citation Analysis]
75 Peng S, Ouyang B, Xin Y, Zhao W, Shen S, Zhan M, Lu L. Hypoxia-degradable and long-circulating zwitterionic phosphorylcholine-based nanogel for enhanced tumor drug delivery. Acta Pharm Sin B 2021;11:560-71. [PMID: 33643831 DOI: 10.1016/j.apsb.2020.08.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
76 Cui SY, Huang JY, Chen YT, Song HZ, Huang GC, De W, Wang R, Chen LB. The role of Aurora A in hypoxia-inducible factor 1α-promoting malignant phenotypes of hepatocelluar carcinoma. Cell Cycle 2013;12:2849-66. [PMID: 23966163 DOI: 10.4161/cc.25916] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
77 Muto J, Shirabe K, Sugimachi K, Maehara Y. Review of angiogenesis in hepatocellular carcinoma. Hepatol Res. 2015;45:1-9. [PMID: 24533487 DOI: 10.1111/hepr.12310] [Cited by in Crossref: 44] [Cited by in F6Publishing: 48] [Article Influence: 5.5] [Reference Citation Analysis]
78 Kim GM, Kim MD, Kim do Y, Kim SH, Won JY, Park SI, Lee do Y, Shin W, Shin M. Transarterial Chemoembolization Using Sorafenib in a Rabbit VX2 Liver Tumor Model: Pharmacokinetics and Antitumor Effect. J Vasc Interv Radiol 2016;27:1086-92. [PMID: 27179404 DOI: 10.1016/j.jvir.2016.02.032] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
79 Chegai F, Orlacchio A, Merolla S, Monti S, Mannelli L. Intermediate hepatocellular carcinoma: the role of transarterial therapy. Hepat Oncol 2015;2:399-408. [PMID: 26998220 DOI: 10.2217/hep.15.32] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
80 Mylonis I, Lakka A, Tsakalof A, Simos G. The dietary flavonoid kaempferol effectively inhibits HIF-1 activity and hepatoma cancer cell viability under hypoxic conditions. Biochemical and Biophysical Research Communications 2010;398:74-8. [DOI: 10.1016/j.bbrc.2010.06.038] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 4.6] [Reference Citation Analysis]
81 Antonucci F, Cento V, Sorbo MC, Manuelli MC, Lenci I, Sforza D, Di Carlo D, Milana M, Manzia TM, Angelico M, Tisone G, Perno CF, Ceccherini-Silberstein F. HCV-RNA quantification in liver bioptic samples and extrahepatic compartments, using the abbott RealTime HCV assay. J Virol Methods 2017;246:1-7. [PMID: 28408312 DOI: 10.1016/j.jviromet.2017.04.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
82 Qin L, Mei L, Shan Z, Huang Y, Pan X, Li G, Gu Y, Wu C. Phytantriol based liquid crystal provide sustained release of anticancer drug as a novel embolic agent. Drug Dev Ind Pharm 2016;42:307-16. [PMID: 26035332 DOI: 10.3109/03639045.2015.1052079] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
83 Takagi K, Takayama T, Nagase H, Moriguchi M, Wang X, Hirayanagi K, Suzuki T, Hasegawa H, Ochiai T, Yamaguchi N, Kochi M, Kimura M, Esumi M. High TSC22D3 and low GBP1 expression in the liver is a risk factor for early recurrence of hepatocellular carcinoma. Exp Ther Med 2011;2:425-31. [PMID: 22977521 DOI: 10.3892/etm.2011.236] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
84 Wu S, Ma Y, Fang Y, Liu L, Fu D, Shen X. Role of the microenvironment in hepatocellular carcinoma development and progression. Cancer Treatment Reviews 2012;38:218-25. [DOI: 10.1016/j.ctrv.2011.06.010] [Cited by in Crossref: 74] [Cited by in F6Publishing: 72] [Article Influence: 7.4] [Reference Citation Analysis]
85 Li X, Li C, Zhang L, Wu M, Cao K, Jiang F, Chen D, Li N, Li W. The significance of exosomes in the development and treatment of hepatocellular carcinoma. Mol Cancer 2020;19:1. [PMID: 31901224 DOI: 10.1186/s12943-019-1085-0] [Cited by in Crossref: 70] [Cited by in F6Publishing: 44] [Article Influence: 35.0] [Reference Citation Analysis]
86 Zhou C, Zhang H, Lu L. Identification and Validation of Hypoxia-Related lncRNA Signature as a Prognostic Model for Hepatocellular Carcinoma. Front Genet 2021;12:744113. [PMID: 34650600 DOI: 10.3389/fgene.2021.744113] [Reference Citation Analysis]
87 Chen JC, Chuang HY, Hsu FT, Chen YC, Chien YC, Hwang JJ. Sorafenib pretreatment enhances radiotherapy through targeting MEK/ERK/NF-κB pathway in human hepatocellular carcinoma-bearing mouse model. Oncotarget 2016;7:85450-63. [PMID: 27863427 DOI: 10.18632/oncotarget.13398] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
88 Song J, Guo X, Xie X, Zhao X, Li D, Deng W, Song Y, Shen F, Wu M, Wei L. Autophagy in hypoxia protects cancer cells against apoptosis induced by nutrient deprivation through a Beclin1-dependent way in hepatocellular carcinoma. J Cell Biochem 2011;112:3406-20. [PMID: 21769915 DOI: 10.1002/jcb.23274] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
89 Li Q, Jin L, Jin M. Novel Hypoxia-Related Gene Signature for Risk Stratification and Prognosis in Hepatocellular Carcinoma. Front Genet 2021;12:613890. [PMID: 34194464 DOI: 10.3389/fgene.2021.613890] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
90 Wang J, Zhao H, Yu J, Xu X, Liu W, Jing H, Li N, Tang Y, Li Y, Cai J, Jin J. MiR-92b targets p57kip2 to modulate the resistance of hepatocellular carcinoma (HCC) to ionizing radiation (IR) -based radiotherapy. Biomed Pharmacother 2019;110:646-55. [PMID: 30544064 DOI: 10.1016/j.biopha.2018.11.080] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
91 Oishi N, Wang XW. Novel therapeutic strategies for targeting liver cancer stem cells. Int J Biol Sci 2011;7:517-35. [PMID: 21552419 DOI: 10.7150/ijbs.7.517] [Cited by in Crossref: 95] [Cited by in F6Publishing: 94] [Article Influence: 8.6] [Reference Citation Analysis]
92 Novikova MV, Khromova NV, Kopnin PB. Components of the Hepatocellular Carcinoma Microenvironment and Their Role in Tumor Progression. Biochemistry (Mosc) 2017;82:861-73. [PMID: 28941454 DOI: 10.1134/S0006297917080016] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 6.2] [Reference Citation Analysis]
93 Tijeras-Raballand A, Hainaud-Hakim P, Contreres JO, Gest C, Le Henaff C, Levy BI, Pocard M, Soria C, Dupuy E. Rosuvastatin counteracts vessel arterialisation and sinusoid capillarisation, reduces tumour growth, and prolongs survival in murine hepatocellular carcinoma. Gastroenterol Res Pract. 2010;2010:640797. [PMID: 21528105 DOI: 10.1155/2010/640797] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
94 Zhang X, Ng HLH, Lu A, Lin C, Zhou L, Lin G, Zhang Y, Yang Z, Zhang H. Drug delivery system targeting advanced hepatocellular carcinoma: Current and future. Nanomedicine. 2016;12:853-869. [PMID: 26772424 DOI: 10.1016/j.nano.2015.12.381] [Cited by in Crossref: 66] [Cited by in F6Publishing: 61] [Article Influence: 11.0] [Reference Citation Analysis]
95 Bonnet S. Why develop photoactivated chemotherapy? Dalton Trans 2018;47:10330-43. [PMID: 29978870 DOI: 10.1039/c8dt01585f] [Cited by in Crossref: 107] [Cited by in F6Publishing: 31] [Article Influence: 26.8] [Reference Citation Analysis]
96 Xu H, Zhao L, Fang Q, Sun J, Zhang S, Zhan C, Liu S, Zhang Y. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α. PLoS One 2014;9:e115565. [PMID: 25531114 DOI: 10.1371/journal.pone.0115565] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 7.3] [Reference Citation Analysis]
97 Dai CX, Gao Q, Qiu SJ, Ju MJ, Cai MY, Xu YF, Zhou J, Zhang BH, Fan J. Hypoxia-inducible factor-1 alpha, in association with inflammation, angiogenesis and MYC, is a critical prognostic factor in patients with HCC after surgery. BMC Cancer 2009;9:418. [PMID: 19948069 DOI: 10.1186/1471-2407-9-418] [Cited by in Crossref: 79] [Cited by in F6Publishing: 85] [Article Influence: 6.1] [Reference Citation Analysis]
98 Ponziani FR, Nicoletti A, Gasbarrini A, Pompili M. Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma. Ther Adv Med Oncol. 2019;11:1758835919848184. [PMID: 31205505 DOI: 10.1177/1758835919848184] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
99 Barbetta A, Goldbeck C, Lim A, Martin SP, Kahn JA, Sheikh MR, Emamaullee J. Treatment and outcomes of hepatocellular carcinoma in patients with Sickle cell disease: a population-based study in the U.S. HPB (Oxford) 2021:S1365-182X(21)00602-X. [PMID: 34294525 DOI: 10.1016/j.hpb.2021.06.420] [Reference Citation Analysis]
100 Lee WH, Byun HK, Choi JS, Choi GH, Han DH, Joo DJ, Kim DY, Han KH, Seong J. Liver-directed combined radiotherapy as a bridge to curative surgery in locally advanced hepatocellular carcinoma beyond the Milan criteria. Radiother Oncol 2020;152:1-7. [PMID: 32739317 DOI: 10.1016/j.radonc.2020.07.046] [Cited by in Crossref: 6] [Article Influence: 3.0] [Reference Citation Analysis]
101 Ju C, Colgan SP, Eltzschig HK. Hypoxia-inducible factors as molecular targets for liver diseases. J Mol Med (Berl). 2016;94:613-627. [PMID: 27094811 DOI: 10.1007/s00109-016-1408-1] [Cited by in Crossref: 65] [Cited by in F6Publishing: 66] [Article Influence: 10.8] [Reference Citation Analysis]
102 Hu F, Deng X, Yang X, Jin H, Gu D, Lv X, Wang C, Zhang Y, Huo X, Shen Q, Luo Q, Zhao F, Ge T, Zhao F, Chu W, Shu H, Yao M, Fan J, Qin W. Hypoxia upregulates Rab11-family interacting protein 4 through HIF-1α to promote the metastasis of hepatocellular carcinoma. Oncogene 2015;34:6007-17. [PMID: 25745995 DOI: 10.1038/onc.2015.49] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
103 Dhamecha D, Le D, Movsas R, Gonsalves A, Menon JU. Porous Polymeric Microspheres With Controllable Pore Diameters for Tissue Engineered Lung Tumor Model Development. Front Bioeng Biotechnol 2020;8:799. [PMID: 32754585 DOI: 10.3389/fbioe.2020.00799] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
104 Lin D, Wu J. Hypoxia inducible factor in hepatocellular carcinoma: A therapeutic target. World J Gastroenterol 2015; 21(42): 12171-12178 [PMID: 26576101 DOI: 10.3748/wjg.v21.i42.12171] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 70] [Article Influence: 8.4] [Reference Citation Analysis]
105 Abraham JA, Yeghiazaryan K, Golubnitschaja O. Selective internal radiation therapy in treatment of hepatocellular carcinoma: new concepts of personalization. Per Med 2016;13:347-60. [PMID: 29749819 DOI: 10.2217/pme-2016-0014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
106 Xu W, Zhou W, Cheng M, Wang J, Liu Z, He S, Luo X, Huang W, Chen T, Yan W, Xiao J. Hypoxia activates Wnt/β-catenin signaling by regulating the expression of BCL9 in human hepatocellular carcinoma. Sci Rep 2017;7:40446. [PMID: 28074862 DOI: 10.1038/srep40446] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 7.0] [Reference Citation Analysis]
107 Dou C, Zhou Z, Xu Q, Liu Z, Zeng Y, Wang Y, Li Q, Wang L, Yang W, Liu Q, Tu K. Hypoxia-induced TUFT1 promotes the growth and metastasis of hepatocellular carcinoma by activating the Ca2+/PI3K/AKT pathway. Oncogene. 2019;38:1239-1255. [PMID: 30250300 DOI: 10.1038/s41388-018-0505-8] [Cited by in Crossref: 42] [Cited by in F6Publishing: 51] [Article Influence: 10.5] [Reference Citation Analysis]
108 Liapi E, Geschwind JF. Intra-arterial therapies for hepatocellular carcinoma: where do we stand? Ann Surg Oncol. 2010;17:1234-1246. [PMID: 20405328 DOI: 10.1245/s10434-010-0977-4] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 4.6] [Reference Citation Analysis]
109 Lv Z, Weng X, Du C, Zhang C, Xiao H, Cai X, Ye S, Cheng J, Ding C, Xie H, Zhou L, Wu J, Zheng S. Downregulation of HDAC6 promotes angiogenesis in hepatocellular carcinoma cells and predicts poor prognosis in liver transplantation patients: HDAC6 INHIBITION PROMOTES HCC ANGIOGENESIS. Mol Carcinog 2016;55:1024-33. [DOI: 10.1002/mc.22345] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
110 Zhang D, Zheng A, Li J, Wu M, Wu L, Wei Z, Liao N, Zhang X, Cai Z, Yang H, Liu G, Liu X, Liu J. Smart Cu(II)-aptamer complexes based gold nanoplatform for tumor micro-environment triggered programmable intracellular prodrug release, photodynamic treatment and aggregation induced photothermal therapy of hepatocellular carcinoma. Theranostics 2017;7:164-79. [PMID: 28042325 DOI: 10.7150/thno.17099] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 8.8] [Reference Citation Analysis]
111 Gao L, Song JR, Zhang JW, Zhao X, Zhao QD, Sun K, Deng WJ, Li R, Lv G, Cheng HY, Wei LX. Chloroquine promotes the anticancer effect of TACE in a rabbit VX2 Liver tumor model. Int J Biol Sci. 2013;9:322-330. [PMID: 23569437 DOI: 10.7150/ijbs.5925] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
112 Li YL, Zhang NY, Hu X, Chen JL, Rao MJ, Wu LW, Li QY, Zhang B, Yan W, Zhang C. Evodiamine induces apoptosis and promotes hepatocellular carcinoma cell death induced by vorinostat via downregulating HIF-1α under hypoxia. Biochem Biophys Res Commun 2018;498:481-6. [PMID: 29505792 DOI: 10.1016/j.bbrc.2018.03.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
113 Yip D, Cho CH. A multicellular 3D heterospheroid model of liver tumor and stromal cells in collagen gel for anti-cancer drug testing. Biochem Biophys Res Commun 2013;433:327-32. [PMID: 23501105 DOI: 10.1016/j.bbrc.2013.03.008] [Cited by in Crossref: 151] [Cited by in F6Publishing: 138] [Article Influence: 16.8] [Reference Citation Analysis]
114 Wang SH, Chen LM, Yang WK, Lee JD. Increased extrinsic apoptotic pathway activity in patients with hepatocellular carcinoma following transarterial embolization. World J Gastroenterol 2011; 17(42): 4675-4681 [PMID: 22180709 DOI: 10.3748/wjg.v17.i42.4675] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
115 Dou C, Liu Z, Xu M, Jia Y, Wang Y, Li Q, Yang W, Zheng X, Tu K, Liu Q. miR-187-3p inhibits the metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting S100A4. Cancer Lett. 2016;381:380-390. [PMID: 27544906 DOI: 10.1016/j.canlet.2016.08.011] [Cited by in Crossref: 65] [Cited by in F6Publishing: 71] [Article Influence: 10.8] [Reference Citation Analysis]
116 Liu K, Zhang X, Xu W, Chen J, Yu J, Gamble JR, McCaughan GW. Targeting the vasculature in hepatocellular carcinoma treatment: Starving vs normalizing blood supply.Clin Transl Gastroenterol. 2017;8:e98. [DOI: 10.1038/ctg.2017.28] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 8.4] [Reference Citation Analysis]
117 Yu Y, Zhang C, Liu L, Li X. Hepatic arterial administration of ginsenoside Rg3 and transcatheter arterial embolization for the treatment of VX2 liver carcinomas. Exp Ther Med 2013;5:761-6. [PMID: 23404440 DOI: 10.3892/etm.2012.873] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
118 Liu Z, Wang Y, Dou C, Xu M, Sun L, Wang L, Yao B, Li Q, Yang W, Tu K, Liu Q. Hypoxia-induced up-regulation of VASP promotes invasiveness and metastasis of hepatocellular carcinoma. Theranostics 2018;8:4649-63. [PMID: 30279729 DOI: 10.7150/thno.26789] [Cited by in Crossref: 35] [Cited by in F6Publishing: 48] [Article Influence: 8.8] [Reference Citation Analysis]
119 Strebel BM, Dufour JF. Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease. Expert Rev Anticancer Ther. 2008;8:1743-1749. [PMID: 18983234 DOI: 10.1586/14737140.8.11.1743] [Cited by in Crossref: 55] [Cited by in F6Publishing: 58] [Article Influence: 4.2] [Reference Citation Analysis]
120 Feng Y, Wang N, Ye X, Li H, Feng Y, Cheung F, Nagamatsu T. Hepatoprotective effect and its possible mechanism of Coptidis rhizoma aqueous extract on carbon tetrachloride-induced chronic liver hepatotoxicity in rats. J Ethnopharmacol 2011;138:683-90. [PMID: 21963555 DOI: 10.1016/j.jep.2011.09.032] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 4.6] [Reference Citation Analysis]
121 Lee SH, Hayano K, Zhu AX, Sahani DV, Yoshida H. Water-Exchange-Modified Kinetic Parameters from Dynamic Contrast-Enhanced MRI as Prognostic Biomarkers of Survival in Advanced Hepatocellular Carcinoma Treated with Antiangiogenic Monotherapy. PLoS One. 2015;10:e0136725. [PMID: 26366997 DOI: 10.1371/journal.pone.0136725] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
122 Van de Veire S, Stalmans I, Heindryckx F, Oura H, Tijeras-raballand A, Schmidt T, Loges S, Albrecht I, Jonckx B, Vinckier S, Van Steenkiste C, Tugues S, Rolny C, De Mol M, Dettori D, Hainaud P, Coenegrachts L, Contreres J, Van Bergen T, Cuervo H, Xiao W, Le Henaff C, Buysschaert I, Masouleh BK, Geerts A, Schomber T, Bonnin P, Lambert V, Haustraete J, Zacchigna S, Rakic J, Jiménez W, Noël A, Giacca M, Colle I, Foidart J, Tobelem G, Morales-ruiz M, Vilar J, Maxwell P, Vinores SA, Carmeliet G, Dewerchin M, Claesson-welsh L, Dupuy E, Van Vlierberghe H, Christofori G, Mazzone M, Detmar M, Collen D, Carmeliet P. Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease. Cell 2010;141:178-90. [DOI: 10.1016/j.cell.2010.02.039] [Cited by in Crossref: 179] [Cited by in F6Publishing: 175] [Article Influence: 14.9] [Reference Citation Analysis]
123 Xie Y, Zhang J, Ye S, He M, Ren R, Yuan D, Shao C. SirT1 regulates radiosensitivity of hepatoma cells differently under normoxic and hypoxic conditions. Cancer Sci 2012;103:1238-44. [PMID: 22448750 DOI: 10.1111/j.1349-7006.2012.02285.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
124 Lewandowski RJ, Geschwind JF, Liapi E, Salem R. Transcatheter intraarterial therapies: rationale and overview. Radiology 2011;259:641-57. [PMID: 21602502 DOI: 10.1148/radiol.11081489] [Cited by in Crossref: 140] [Cited by in F6Publishing: 132] [Article Influence: 12.7] [Reference Citation Analysis]
125 Dewerchin M, Carmeliet P. PlGF: a multitasking cytokine with disease-restricted activity. Cold Spring Harb Perspect Med. 2012;2. [PMID: 22908198 DOI: 10.1101/cshperspect.a011056] [Cited by in Crossref: 127] [Cited by in F6Publishing: 126] [Article Influence: 12.7] [Reference Citation Analysis]
126 Li H, Ge C, Zhao F, Yan M, Hu C, Jia D, Tian H, Zhu M, Chen T, Jiang G. Hypoxia-inducible factor 1 alpha-activated angiopoietin-like protein 4 contributes to tumor metastasis via vascular cell adhesion molecule-1/integrin β1 signaling in human hepatocellular carcinoma. Hepatology. 2011;54:910-919. [PMID: 21674552 DOI: 10.1002/hep.24479] [Cited by in Crossref: 103] [Cited by in F6Publishing: 100] [Article Influence: 10.3] [Reference Citation Analysis]
127 Zhang X, Li S, Li M, Huang H, Li J, Zhou C. Hypoxia-inducible factor-1α mediates the toll-like receptor 4 signaling pathway leading to anti-tumor effects in human hepatocellular carcinoma cells under hypoxic conditions. Oncol Lett 2016;12:1034-40. [PMID: 27446390 DOI: 10.3892/ol.2016.4705] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]